Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence.

Abstract:

:The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is not fully differentiated until after the first full-term pregnancy; thus, breast tissue might be more susceptible to carcinogenic influences during early life and adolescence. Birth characteristics of the daughter, including gestational age, birth weight, and birth length are associated with maternal hormone levels during the index pregnancy, and birth size has been related to daughter's timing of puberty and adult breast cancer incidence. Furthermore, early life and adolescence are critical times for maturation of the hypothalamic pituitary ovarian axis, which regulates production of ovarian hormones including estrogen and progesterone. Childhood height, growth, diet, and body mass index (BMI) have also been associated with breast cancer risk later in life. Of the examined characteristics, we conclude that the available evidence is suggestive of a positive relationship of breast cancer risk with birth weight, birth length, and adolescent height, and an inverse relationship with gestational age and childhood BMI, although several inconsistencies exist in the literature. The best evidence for a relationship of adolescent diet and adult breast cancer risk is indirect, and the relationship of diet, weight status, and weight gain in childhood deserves further attention. The interaction of birth characteristics with established risk factors over the life course, such as age at menarche, in addition to gene-environment interactions, require more research. Further study is also needed to clarify the biologic mechanisms influencing the observed associations.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Ruder EH,Dorgan JF,Kranz S,Kris-Etherton PM,Hartman TJ

doi

10.3816/CBC.2008.n.038

subject

Has Abstract

pub_date

2008-08-01 00:00:00

pages

334-42

issue

4

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)70526-2

journal_volume

8

pub_type

杂志文章,评审
  • Five-Year Oncologic Outcomes of Volume Displacement Procedures After Partial Mastectomy for Breast Cancer.

    abstract:BACKGROUND:Volume displacement techniques that use remnant breast tissue are useful in reconstructive procedures after partial mastectomy. The authors analyzed the oncologic results of volume displacement surgery after partial mastectomy and their associations with various clinicopathologic factors. PATIENTS AND METHO...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.06.018

    authors: Lee J,Jung JH,Kim WW,Hwang SO,Chae YS,Lee SJ,Yang JD,Lee JW,Park HY

    更新日期:2017-02-01 00:00:00

  • Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.

    abstract::Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.05.012

    authors: Tang Y,Wang Y,Kiani MF,Wang B

    更新日期:2016-10-01 00:00:00

  • Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.

    abstract:PURPOSE:The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system requires histologic grade (GR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and stage (assessed by the tumor, node, metastasis classification system). For T1-2 N...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.10.005

    authors: Breaux A,Turner B,Wu X,Rai SN,Riley EC,Mandadi M,Sanders MA

    更新日期:2019-02-01 00:00:00

  • A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

    abstract:BACKGROUND:Three-drug regimens containing gemcitabine, an anthracycline, and a taxane produce response rates of 70%-90% in patients with metastatic breast cancer (MBC) although accompanied by considerable hematologic toxicity. We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docet...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CBC.2010.n.029

    authors: Yardley DA,Peacock NW,Dickson NR,White MB,Vázquez ER,Foust JT,Grapski R,Hendricks LK,Scott WL,Hainsworth JD

    更新日期:2010-06-01 00:00:00

  • Comprehensive review of sentinel lymphadenectomy in breast cancer.

    abstract::Sentinel lymph node dissection (SLND) is a minimally invasive technique to stage axillary lymph nodes in breast cancer. The complications associated with SLND are minimal, especially when compared to routine axillary lymph node dissection (ALND), and it can be performed with an overall identification rate of greater t...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2000.n.010

    authors: Kelemen PR

    更新日期:2000-07-01 00:00:00

  • Breast Reconstruction Actualized in Nipple-sparing Mastectomy and Direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results.

    abstract:BACKGROUND:Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.12.015

    authors: de Vita R,Buccheri EM,Villanucci A,Pozzi M

    更新日期:2019-04-01 00:00:00

  • Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.

    abstract::Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2008.s.001

    authors: Andreopoulou E,Muggia F

    更新日期:2008-03-01 00:00:00

  • Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review.

    abstract::Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system frequently complicated by devastating neurologic symptoms and progressive disability. Much progress has been made in the development of immunomodulating drugs to help fight the progression of MS. These drugs are believed to wor...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.055

    authors: Amaria RN,Corboy JR,Finlayson CA,Robinson WA,Borges VF

    更新日期:2008-10-01 00:00:00

  • Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.

    abstract:BACKGROUND:Nanosomal docetaxel lipid suspension formulation was developed to eliminate ethanol and polysorbate 80 from the currently used docetaxel (Taxotere) drug for treatment of cancer patients. NDLS clinical safety and efficacy was evaluated and compared with Taxotere at 75 mg/m(2) in metastatic breast cancer patie...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.09.011

    authors: Ahmad A,Sheikh S,Taran R,Srivastav SP,Prasad K,Rajappa SJ,Kumar V,Gopichand M,Paithankar M,Sharma M,Rane RC,Ahmad I

    更新日期:2014-06-01 00:00:00

  • JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.

    abstract:BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.05.006

    authors: Chen M,Pockaj B,Andreozzi M,Barrett MT,Krishna S,Eaton S,Niu R,Anderson KS

    更新日期:2018-10-01 00:00:00

  • A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.

    abstract::This article discusses the rationale for 2 methods of making estimates of the benefit of letrozole as extended adjuvant hormonal therapy after 5 years of tamoxifen. It uses information from the Overview metaanalyses to develop general rules for making estimates of remaining risk of relapse for women completing 5 years...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/cbc.2004.n.047

    authors: Ravdin PM,Davis GJ

    更新日期:2004-10-01 00:00:00

  • CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    abstract:BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clbc.2018.04.017

    authors: Deng Y,Ma G,Li W,Wang T,Zhao Y,Wu Q

    更新日期:2018-10-01 00:00:00

  • Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry.

    abstract:BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.008

    authors: Barcenas CH,Wells J,Chong D,French J,Looney SW,Samuel TA

    更新日期:2010-02-01 00:00:00

  • Advances in radiation treatments of breast cancer.

    abstract::During the past decade, improvements in treatment-planning tools, computer and imaging technologies, and new therapeutic modalities have allowed radiation to be delivered in a conformal fashion while minimizing treatment toxicity. It is important that physicians involved in breast cancer treatment recognize the numero...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.002

    authors: Frank SJ,McNeese MD,Strom EA,Perkins G,Salehpour M,Schechter N,Buchholz TA

    更新日期:2004-02-01 00:00:00

  • A Guide to Prepectoral Breast Reconstruction: A New Dimension to Implant-based Breast Reconstruction.

    abstract::Acellular dermal matrix has revolutionized implant-based breast reconstruction. Breast reconstruction has evolved from the traditional submuscular to the new prepectoral implant based (also known as muscle-sparing) reconstruction. The new technique is emerging as a highly popular surgery owing to its more minimal appr...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.11.009

    authors: Vidya R,Iqbal FM

    更新日期:2017-07-01 00:00:00

  • Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3.

    abstract:BACKGROUND:Patients with breast cancer with pathologic N3 (pN3) lymph node status have been proven to have a poor prognosis. This study aimed to establish a nomogram to predict overall survival (OS) in patients with pN3 breast cancer. MATERIALS AND METHODS:The eligible patients from the Surveillance, Epidemiology, and...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.06.002

    authors: Wang J,Chen L,Nie Y,Wu W,Yao Y

    更新日期:2020-12-01 00:00:00

  • A case of chylous fistula after axillary dissection in breast-conserving treatment for breast cancer.

    abstract::Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.030

    authors: Donkervoort SC,Roos D,Borgstein PJ

    更新日期:2006-06-01 00:00:00

  • Mammography Coverage and Tumor Stage in the Opportunistic Screening Context.

    abstract:INTRODUCTION:The increment of breast cancer screening coverage should lead to an increase in the proportion of early tumors diagnosed and the decrease of the cancer-related mortality. However, the effectiveness of opportunistic mammography screening is not well documented for public health systems in middle-income coun...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.04.014

    authors: Magario MB,Poli-Neto OB,Tiezzi DG,Angotti Carrara HH,Moreira de Andrade J,Candido Dos Reis FJ

    更新日期:2019-12-01 00:00:00

  • Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.

    abstract::The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations. Epirubicin is associated with less cardiotoxicity than doxorubicin and ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2000.s.010

    authors: Perez EA

    更新日期:2000-09-01 00:00:00

  • Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.

    abstract:BACKGROUND:This study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability. PATIENTS AND METHODS:All patients that received NPLD for MBC at 5 institutions were identi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2013.10.011

    authors: Palmieri C,Misra V,Januszewski A,Yosef H,Ashford R,Keary I,Davidson N

    更新日期:2014-04-01 00:00:00

  • Breast cancer in adolescent and young adult women.

    abstract::Breast cancer is one of the most frequently diagnosed malignancy among adolescent and young adult (AYA) women, accounting for approximately 14% of all AYA cancer diagnoses and 7% of all breast cancer. Breast cancer in AYA women is believed to represent a more biologically aggressive disease, but aside from commonly kn...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2014.06.002

    authors: Gewefel H,Salhia B

    更新日期:2014-12-01 00:00:00

  • Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.

    abstract::A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer I...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2001.n.008

    authors: Ross PJ,Powles TJ

    更新日期:2001-04-01 00:00:00

  • The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.

    abstract::The development of third-generation aromatase inhibitors (AIs) has brought about a major change in the therapeutic approach to patients with hormone-sensitive breast cancer. In randomized clinical trials, each of the third-generation AIs has demonstrated efficacy in the adjuvant treatment of postmenopausal women with ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.022

    authors: Henderson IC,Piccart-Gebhart MJ

    更新日期:2005-08-01 00:00:00

  • Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

    abstract:BACKGROUND:Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction. We investigated the impact of a 3-month letrozole-free interval on serum estradiol levels in patients with early stage breast cancer. PATIENTS AND METHOD...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.03.007

    authors: Balduzzi A,Bagnardi V,Sandri MT,Dellapasqua S,Cardillo A,Montagna E,Cancello G,Iorfida M,Ghisini R,Viale G,Intra M,Luini A,Goldhirsch A,Colleoni M

    更新日期:2015-10-01 00:00:00

  • Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.

    abstract:INTRODUCTION:The purpose of the study was to determine predictors of recurrence for patients treated with neoadjuvant chemotherapy (NAC) and mastectomy according to the use of postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS:An analysis of 161 clinically staged T1 to T3/N0 to N3 patients treated with NAC ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.09.012

    authors: Nagar H,Boothe D,Ginter PS,Sison C,Vahdat L,Shin S,Smith M,Chao KS,Nori D,Hayes MK

    更新日期:2015-04-01 00:00:00

  • The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.

    abstract::Trastuzumab improves survival outcomes for patients with HER2-positive (HER2+) breast cancer, yet not all such women receive this important therapy. Trastuzumab was approved by the US Food and Drug Administration in 1998 and the European Medicines Agency in 2000 as treatment for HER2+ metastatic breast cancer (MBC). O...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2018.01.006

    authors: Blackwell K,Gligorov J,Jacobs I,Twelves C

    更新日期:2018-04-01 00:00:00

  • Timing of Postmastectomy Reconstruction Does Not Impair Breast Cancer-Specific Survival: A Population-Based Study.

    abstract:BACKGROUND:Debate remains over the optimal timing of breast reconstruction after mastectomy. Immediate reconstruction has demonstrated superior psychosocial and aesthetic outcomes, but might delay adjuvant therapy. Conversely, delayed reconstruction allows for timely initiation of adjuvant therapy, but with potentially...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.003

    authors: Bezuhly M,Wang Y,Williams JG,Sigurdson LJ

    更新日期:2015-12-01 00:00:00

  • Comparison of HER2 detection methods between central and regional laboratories in Greece.

    abstract:PURPOSE:HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and th...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.040

    authors: Papadopoulos S,Kouvatseas G,Skarlos D,Malamos N,Delliou E,Saratsiotou I,Ardavanis A,Mavroudis D,Skarpidi E,Arapantoni P,Karyda I,Patakioyta F,Aravantinos G,Razis E,Fountzilas G,Kosmidis P

    更新日期:2007-10-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.04.008

    authors: Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期:2015-12-01 00:00:00

  • Nipple Discharge After Nipple-Sparing Mastectomy With and Without Associated Pregnancy.

    abstract:BACKGROUND:Nipple-sparing mastectomies (NSMs) preserve the intact nipple, including nipple duct orifices. Retained orifices might remain patent and communicate with the underlying reconstruction. We report the incidence and outcomes of nipple discharge after NSM in pregnant and nonpregnant women. PATIENTS AND METHODS:...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.03.003

    authors: Tang R,Kelly BN,Smith BL,Lanahan CR,Brown CL,Gadd MA,Hughes KS,Oseni TO,McGugin C,Specht MC,Coopey SB

    更新日期:2019-08-01 00:00:00